Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study

Simon Redwood interviews John Forrest, principal investigator of the Evolut Low Risk Bicuspid Study, during #europcr 2025. As TAVR moves into younger patients—many with bicuspid valves—questions remain about how well the procedure performs in this anatomy, which was excluded from earlier trials. In this exchange, they review the study design, patient selection, and main outcomes, and compare results with the original Evolut Low Risk study. The performance of the Evolut platform in bicuspid valves may even prove superior to tricuspid cases—though long-term follow-up is essential. Valve thrombosis is also on the table. Listen to this episode now to explore the current data and what’s still to come! Hosted on Acast. See acast.com/privacy for more information.